Novartis India Peer Comparison

NSE: NOVARTIND | BSE: 500672

₹1,824.50

₹140.00 (8.31%)

As on 23-Oct-2026IST

Market cap

₹4,530 Cr

Revenue (TTM)

₹371 Cr

P/E Ratio

46.3

P/B Ratio

5.3

Div. Yield

0 %

Edit

	Novartis India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Market cap (₹ Cr)	4,530	29,269	25,696	25,409	23,588
Revenue (₹ Cr)	371	3,564	1,462	9,205	1,936
Net Profit (₹ Cr)	97.77	414.00	387.35	-371.81	288.22
Net Margin (%)	23.99	11.23	26.01	-3.93	14.79
RoE (%)	12.28	8.38	25.18	-3.85	29.77
Price to Earnings	46.33	71.56	66.53	--	81.84
Price-To-Book	5.33	5.81	14.89	3.17	17.57

Income Statement (₹ Cr)

	Novartis India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Operating Revenue	370.59	3,564.00	1,461.80	9,205.28	1,935.80
Total Income	407.49	3,686.00	1,489.25	9,449.59	1,948.58
Total Expenditure	268.82	2,792.00	919.25	8,195.15	1,485.56
EBITDA	101.77	772.00	542.56	1,010.13	450.24
Depreciation	1.84	226.00	37.68	857.51	50.83
EBIT	99.93	546.00	504.88	152.62	399.41
Interest	1.22	217.00	3.77	342.73	40.84
Other Income	36.90	122.00	27.45	244.31	12.78
Exceptional Items	0.00	12.00	0.00	-216.88	0.00
Profit before Tax	135.61	463.00	528.56	-162.68	371.35
Provision for Tax	37.84	49.00	141.21	209.13	83.14
Profit after Tax	97.77	414.00	387.35	-371.81	288.22

	Novartis India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Shareholder's Funds	817.83	4,940.00	1,653.56	8,162.62	1,288.82
Minority Interest	0.00	-5.00	-1.13	0.00	0.00
Non-Current Liabilities	15.47	1,712.00	42.40	5,044.14	202.03
Current Liabilities	144.97	1,622.00	230.82	4,758.28	835.87
Total Liabilities	1,986.80	8,578.00	1,983.96	17,723.32	2,326.71

	Novartis India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Non-Current Assets	14.29	5,343.00	1,026.85	10,211.52	519.60
Current Assets	768.25	2,606.00	881.27	7,191.66	1,681.81
Total Assets	1,986.80	8,578.00	1,983.96	17,723.32	2,326.71
Total Debt*	0.00	2,125.00	26.49	5,495.48	259.37
Net Current Assets	623.28	984.00	650.46	2,433.38	845.94
Contingent Liabilities	387.55	768.26	17.25	95.72	19.09

	Novartis India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Cash From Operating Activities	46.73	390.00	292.17	1,652.60	205.05
Cash Flow from Investing Activities	17.63	-241.00	-265.94	-826.03	-409.72
Cash from Financing Activities	-63.93	-54.00	4.10	-38.98	283.07
Net Cash Inflow / Outflow	0.43	95.00	30.33	787.59	78.39

	Novartis India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
ROCE (%)	16.34	6.79	32.42	1.24	29.22
ROE (%)	12.28	8.38	25.18	-3.85	29.77
ROA (%)	10.15	4.94	21.93	-2.21	24.77
EBIT Margin (%)	26.97	15.32	34.54	1.66	20.63
Net Margin (%)	23.99	11.23	26.01	-3.93	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Novartis India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Revenue Growth (%)	5.42	18.37	40.90	0.78	46.65
EBIT Growth (%)	8.01	252.26	124.50	-70.53	62.13
Net Profit Growth (%)	-4.87	377.85	104.15	-1,383.43	89.49
EPS Growth (%)	-4.87	1,001.33	42.32	-484.84	78.60
Book Value Growth (%)	4.19	13.47	26.03	0.33	144.31

	Novartis India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Price / Earnings	46.33	73.45	66.53	-81.20	80.58
Price / Book Value	5.33	5.81	14.89	3.17	17.57
Dividend Yield (%)	0.00	0.00	0.08	0.00	0.11
EV/EBITDA	37.95	39.81	46.99	29.25	52.20
Market Cap (₹ Cr)	2,395.94	19,071.62	20,944.75	18,108.89	12,753.19

	Novartis India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debt to Equity	0.00	0.31	0.02	0.53	0.11
Short term debt to equity ratio	--	0.09	0.02	0.09	0.05
Current Ratio	5.30	1.61	3.82	1.51	2.01
Quick Ratio	4.93	1.06	2.82	0.87	1.14
Interest Coverage	112.16	3.13	141.16	0.53	10.09

	Novartis India	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debtors to sales (%)	10.00	16.50	24.80	23.44	26.28
Asset Turnover	0.38	0.43	0.83	0.55	1.66
Receivable days	37.37	58.75	88.98	78.20	40.13
Inventory Days	45.72	75.82	56.04	93.30	60.29
Payable days	97.63	186.21	99.95	226.14	232.47
Cash Conversion Cycle	-14.54	-51.64	45.07	-54.64	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.